乳腺查工作坊中的风险分层
Andrew Anderson1, Cristina Visintin2, Antonis Antoniou3
1UK NSC secretariat, Sheffield/London, UK. Andrew.Anderson@dhsc.gov.uk.
BMC proceedings
|October 24, 2024
概括
风险分层的乳腺癌 (BC) 查旨在根据个体风险量身定制查强度,潜在地改善与当前基于年龄的计划相比,益处和危害的平衡. 需要进一步的研究来完善模型和基础设施,以便有效实施.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 生物统计学 生物统计学
背景情况:
- 目前英国的乳腺癌 (BC) 查针对50-71岁的女性,以减少死亡率.
- 高风险妇女在国家计划中接受额外的查.
- 人们对通过风险分层来个性化查越来越感兴趣.
研究的目的:
- 评估乳腺癌风险分层查策略.
- 通知英国国家查委员会 (UK NSC) 关于潜在的益处和危害.
- 确定实施风险量身定制查的证据缺口.
主要方法:
- 英国国家安全委员会研讨会的记录,讨论了风险预测和决策分析模型.
- 专家讨论了对风险分层计划的利益危害分析和经济评估.
- 审查目前的专家工作和初步数据.
主要成果:
- 专家们讨论了BC查的风险预测和决策分析模型.
- 确定进一步工作的领域包括模型比较,风险评估工具,数字基础设施,可接受性,选测试选择和减少不平等.
- 建议逐步引入现实世界的证据评估,以实现全程序的分层.
结论:
- 风险分层为基于年龄的乳腺癌查提供了潜在的改善.
- 进一步的研究和仔细的规划对于成功实施至关重要.
- 解决发现的差距对于开发有效,公平的风险量身定制的查计划至关重要.
更多相关视频
06:03Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
Published on: February 6, 2020
6.6K
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.6K
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
